- Home
- BATL vs LSTA Comparison
BATL vs LSTA Comparison
Compare BATL & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- LSTA
- Stock Information
- Founded
- BATL 1987
- LSTA 1980
- Country
- BATL United States
- LSTA United States
- Employees
- BATL N/A
- LSTA N/A
- Industry
- BATL Oil & Gas Production
- LSTA Misc Health and Biotechnology Services
- Sector
- BATL Energy
- LSTA Health Care
- Exchange
- BATL Nasdaq
- LSTA Nasdaq
- Market Cap
- BATL 28.8M
- LSTA 31.2M
- IPO Year
- BATL N/A
- LSTA N/A
- Fundamental
- Price
- BATL $1.94
- LSTA $3.71
- Analyst Decision
- BATL
- LSTA Strong Buy
- Analyst Count
- BATL 0
- LSTA 1
- Target Price
- BATL N/A
- LSTA $15.00
- AVG Volume (30 Days)
- BATL 264.4K
- LSTA 53.5K
- Earning Date
- BATL 11-12-2024
- LSTA 02-27-2025
- Dividend Yield
- BATL N/A
- LSTA N/A
- EPS Growth
- BATL N/A
- LSTA N/A
- EPS
- BATL N/A
- LSTA N/A
- Revenue
- BATL $191,482,000.00
- LSTA N/A
- Revenue This Year
- BATL $2.21
- LSTA N/A
- Revenue Next Year
- BATL N/A
- LSTA N/A
- P/E Ratio
- BATL N/A
- LSTA N/A
- Revenue Growth
- BATL N/A
- LSTA N/A
- 52 Week Low
- BATL $1.31
- LSTA $2.19
- 52 Week High
- BATL $9.66
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- BATL 38.92
- LSTA 66.07
- Support Level
- BATL $1.76
- LSTA $3.52
- Resistance Level
- BATL $2.32
- LSTA $3.87
- Average True Range (ATR)
- BATL 0.20
- LSTA 0.29
- MACD
- BATL 0.12
- LSTA 0.02
- Stochastic Oscillator
- BATL 45.71
- LSTA 63.97
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent oil and gas producer operating exclusively in the Delaware Basin. It is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the United States. The company operates in one segment which focuses on oil and natural gas acquisition, production, exploration, and development.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.